PET imaging of CCND1 mRNA in human MCF7 estrogen receptor-positive breast cancer xenografts with oncogene-specific [64Cu]chelator-peptide nucleic acid-IGF1 analog radiohybridization probes

Journal of Nuclear Medicine

Volumn 48, Issue 10, 2007, Pages 1699-1707

  Tian, Xiaobing ^a,b   Aruva, Mohan R ^a   Zhang, Kaijun ^a   Shanthly, Nylla ^a   Cardi, Christopher A ^a   Thakur, Mathew L ^a,c   Wickstrom, Eric ^a,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7 TRIS(CARBOXYMETHYLAZA)CYCLODODECANE 10 AZAACETYL; CHELATING AGENT; COPPER 64; CYCLIN D1; ESTROGEN RECEPTOR; MESSENGER RNA; PEPTIDE NUCLEIC ACID; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; ENDOCYTOSIS; FEMALE; IMAGE ANALYSIS; MOLECULAR PROBE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CHELATING AGENTS; COPPER RADIOISOTOPES; CYCLINS; DIAGNOSTIC TECHNIQUES, RADIOISOTOPE; FEMALE; GENE TARGETING; HUMANS; HYBRIDIZATION, GENETIC; INSULIN-LIKE GROWTH FACTOR I; MICE; PEPTIDE NUCLEIC ACIDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, ESTROGEN; RNA, MESSENGER; TISSUE DISTRIBUTION;

EID: 35348865605     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.042499     Document Type: Article

References (39)

1. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA. 1994;91:709-713.
2. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med. 1995;1:1257-1260.
3. Millikan R, Hulka B, Thor A, et al. p53 mutations in benign breast tissue. J Clin Oncol. 1995;13:2293-2300.
4. Shoker BS, Jarvis C, Davies MP, Iqbal M, Sibson DR, Sloane JP. Immunodetectable cyclin D(1) is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br J Cancer. 2001;84:1064-1069.
5. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia. 2000;5:95-105.
6. Armengol G, Knuutila S, Lluis F, Capella G, Miro R, Caballin MR. DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet Cytogenet. 2000;116:133-141.
7. Wang Y, Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets. 2002;2:191-207.
8. Bhaumik S, Walls Z, Puttaraju M, Mitchell LG, Gambhir SS. Molecular imaging of gene expression in living subjects by spliceosome-mediated RNA trans-splicing. Proc Natl Acad Sci USA. 2004;101:8693-8698.
9. Wickstrom E. Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. New York, NY: Marcel Dekker; 1998.
10. 177Lu-DOTA-gastrin in metastatic medullary thyroid cancer. Available at: www.sgedssed.ch/files/Dota_NOCate2.ppt. Accessed November 5, 2005.
11. Good L, Nielsen PE. Progress in developing PNA as a gene-targeted drug. Antisense Nucleic Acid Drug Dev. 1997;7:431-437.
12. Tian X, Wickstrom E. Continuous solid-phase synthesis and disulfide cyclization of peptide-PNA-peptide chimeras. Org Lett. 2002;4:4013-4016.
13. Gray GD, Basu S, Wickstrom E. Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3′-alkylamino oligodeoxynucleotides, 2′-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. Biochem Pharmacol. 1997;53:1465-1476.
14. Soomets U, Hallbrink M, Langel U. Antisense properties of peptide nucleic acids. Front Biosci. 1999;4:D782-D786.
15. Basu S, Wickstrom E. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjug Chem. 1997;8:481-488.
16. Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA, Baserga R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res. 1992;52:6447-6451.
17. 99mTc-Peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours. Nucl Med Commun. 2003;24:857-863.
18. Guvakova MA, Surmacz E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res. 1997;231:149-162.
19. Soule HD, McGrath CM. Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett. 1980;10:177-189.
20. 99mTc-peptide-peptide nucleic acid-peptide chimeras. J Nucl Med. 2004;45:2070-2082.
21. 99mTc]peptide-peptide nucleic acid-peptide chimera. Bioconjug Chem. 2005;16:70-79.
22. Smith SV. Molecular imaging with copper-64. J Inorg Biochem. 2004;98:1874-1901.
23. 2+ complex with a tetraaza macrocyclic tetraacetate. Acta Crystallogr. 1988;C44:1740-1742.
24. Huisman MC, Reder S, Weber AW, Ziegler SI, Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imaging. 2007;34:532-540.
25. Daube-Witherspoon ME, Mate JS, Karp JS, Lewitt RM. The application of the row action maximum likelihood algorithm with spherical basis functions to clinical PET imaging. IEEE Trans Nucl Sci. 2001;48:24-30.
26. 99mTc-VIP analog. J Nucl Med. 2004;45:1381-1389.
27. Okado-Matsumoto A, Fridovich I. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J Biol Chem. 2001;276:38388-38393.
28. Tian X, Aruva MR, Rao PS, et al. Imaging oncogene expression. In: Cho-Chung YS, Gewirtz AM, Stein CA, eds. Therapeutic Oligonucleotides: Antisense, RNAi, Triple Helix, DNA Decoys, and DNA Chips. Vol 1002. New York, NY: New York Academy of Sciences; 2003:1083-1099.
29. Sun X, Fang H, Li X, Rossin R, Welch MJ, Taylor JS. MicroPET imaging of MCF-7 tumors in mice via unr mRNA-targeted peptide nucleic acids. Bioconjug Chem. 2005;16:294-305.
30. Tufto I, Lyng H, Rofstad EK. Vascular density in human melanoma xenografts: relationship to angiogenesis, perfusion and necrosis. Cancer Lett. 1998;123:159-165.
31. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med. 2007;13:372-377.
32. Li LZJ, Zhong T, Zhou R, et al. Predicting melanoma metastatic potential by optical and magnetic resonance imaging. In: McGuire DJ, Bruley DF, Harrison DK, eds. Oxygen Transport to Tissue XXVIII. Vol. 599. New York, NY: Springer; 2007:67-78.
33. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465-1474.
34. 99mTc-Labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med. 1999;40:352-360.
35. Cutrona G, Boffa LC, Mariani MR, et al. The peptide nucleic acid targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma lacks immunogenicity: follow-up characterization of PNAEmu-NLS. Oligonucleotides. 2007;17:146-150.
36. Boffa LC, Cutrona G, Cilli M, et al. Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma. Oligonucleotides. 2005;15:85-93.
37. Boffa LC, Cutrona G, Cilli M, et al. Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. Cancer Gene Ther. 2007;14:220-226.
38. 64Cu-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213-221.
39. 64Cu for tumor imaging and therapy. J Nucl Med. 2003;44:1284-1292.